Q2 2025 · 13F-HR
Casdin Capital, LLCholdings as filed
Filed 2025-08-14 · accession 0000919574-25-004903
$1.10B
Reported value
33
Positions
2025-06-30
Period end
The Brief · Casdin Capital, LLC · Q2 2025
AI · grounded in 13F
Casdin Capital, LLC established a new position in GENEDX HOLDINGS CORP WGS valued at $323.7M. The fund also initiated new stakes in BIOLIFE SOLUTIONS INC BLFS for $166M and REVOLUTION MEDICINES INC RVMD for $106.2M. Other new additions include STANDARD BIOTOOLS INC LAB and ILLUMINA INC ILMN. Total assets under management stand at $1.1B across 33 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 81663L200 | WGS | GENEDX HOLDINGS CORP | $323.7M | 29.5% | 3,507,164 | Common | SOLE |
| 09062W204 | BLFS | BIOLIFE SOLUTIONS INC | $166.0M | 15.1% | 7,707,165 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $106.2M | 9.68% | 2,887,933 | Common | SOLE |
| 34385P108 | LAB | STANDARD BIOTOOLS INC | $91.3M | 8.31% | 76,075,636 | Common | SOLE |
| 452327109 | ILMN | ILLUMINA INC | $61.5M | 5.60% | 645,000 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $50.4M | 4.59% | 1,775,000 | Common | SOLE |
| 92539P101 | — | VERVE THERAPEUTICS INC | $46.0M | 4.19% | 4,095,571 | Common | SOLE |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $39.4M | 3.59% | 11,398,574 | Common | SOLE |
| 02043Q107 | ALNY | ALNYLAM PHARMACEUTICALS INC | $26.6M | 2.42% | 81,500 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $25.4M | 2.31% | 1,225,000 | Common | SOLE |
| 07373V105 | BEAM | BEAM THERAPEUTICS INC | $24.7M | 2.25% | 1,450,000 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $19.4M | 1.76% | 1,295,361 | Common | SOLE |
| 192005106 | CDXS | CODEXIS INC | $17.6M | 1.60% | 7,200,000 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $16.9M | 1.54% | 990,097 | Common | SOLE |
| 24823R105 | DNLI | DENALI THERAPEUTICS INC | $12.5M | 1.13% | 890,000 | Common | SOLE |
| 433000106 | HIMS | HIMS & HERS HEALTH INC | $11.5M | 1.04% | 230,000 | Common | SOLE |
| 578784100 | MAZE | MAZE THERAPEUTICS INC | $9.3M | 0.85% | 758,857 | Common | SOLE |
| 92337F107 | VCYT | VERACYTE INC | $7.5M | 0.68% | 276,308 | Common | SOLE |
| 532457108 | LLY | ELI LILLY & CO | $6.6M | 0.60% | 8,500 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $6.1M | 0.55% | 650,000 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $5.8M | 0.53% | 553,268 | Common | SOLE |
| 40131M109 | GH | GUARDANT HEALTH INC | $5.2M | 0.47% | 100,000 | Common | SOLE |
| 30063P105 | EXK | EXACT SCIENCES CORP | $4.8M | 0.44% | 90,000 | Common | SOLE |
| 74168J101 | PRME | PRIME MEDICINE INC | $3.9M | 0.35% | 1,567,175 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $3.3M | 0.30% | 100,000 | Common | SOLE |
| 00091E109 | ABSI | ABSCI CORPORATION | $2.5M | 0.23% | 973,260 | Common | SOLE |
| 69404D108 | PACB | PACIFIC BIOSCIENCES CALIF IN | $897,471 | 0.08% | 723,767 | Common | SOLE |
| 75629V104 | RXRX | RECURSION PHARMACEUTICALS IN | $836,534 | 0.08% | 165,323 | Common | SOLE |
| 15673T100 | IPSC | CENTURY THERAPEUTICS INC | $686,190 | 0.06% | 1,228,190 | Common | SOLE |
| 21217B100 | CTNM | CONTINEUM THERAPEUTICS INC | $588,882 | 0.05% | 148,333 | Common | SOLE |
| 37611X209 | DNA | GINKGO BIOWORKS HOLDINGS INC | $410,546 | 0.04% | 36,493 | Common | SOLE |
| 61225M102 | GLUE | MONTE ROSA THERAPEUTICS INC | $387,923 | 0.04% | 86,014 | Common | SOLE |
| 87990A106 | TNYA | TENAYA THERAPEUTICS INC | $221,235 | 0.02% | 361,969 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.